Protalix Biotherapeutics, Inc. (NYSE American:PLX)

About the company

Protalix Biotherapeutics, Inc. engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa and OPRX-106. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Karmiel, Israel.

Sector

Health Services

Industry

Services to the Health Industry

Employees

196

CEO

Dror Bashan

Exchange

NYSE American

Website

http://www.protalix.com

$66.00M

Total Revenue

196

Employees

$55.95M

Market Capitalization

-5.92

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

$54M

Operating Margin (in %)

Total operating margin

$0M

Net Margin (in %)

Total net margin

$-9M

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
IQVIA Holdings, Inc. IQV 28020.96 11158.00 4.88 129.83 1.93
Laboratory Corp. of America Holdings LH 16686.46 11587.00 2.36 52.88 2.77
Quest Diagnostics, Inc. DGX 15781.44 7726.00 2.74 18.48 10.33
Syneos Health, Inc. SYNH 6098.18 4720.00 2.01 30.93 4.13
National Research Corp. NRC 1517.10 130.00 39.43 41.68 27.51
Apollo Medical Holdings, Inc. AMEH 591.12 625.00 2.96 32.84 2.89
Bioanalytical Systems, Inc. BASI 57.64 55.00 5.76 -24.95 -3.94
Protalix Biotherapeutics, Inc. PLX 55.95 66.00 -3.93 -5.92 -14.18
Psychemedics Corp. PMD 34.74 35.00 2.02 41.36 2.14
Interpace Biosciences, Inc. IDXG 24.56 24.00 1.91 -0.85 -112.78
Pressure BioSciences, Inc. PBIO 4.50 2.00 -0.52 -0.28 -876.69

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Protalix BioTherapeutics Inc.

5d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Protalix Finalizes Accelerated Approval Pathway for PRX-102

11d ago, source: YAHOO!

Protalix BioTherapeutics, Inc. PLX and its Italian partner Chiesi Farmaceutici S.p.A. announced that they have successfully completed a type B pre-Biologics License Application (“BLA”) meeting ...

Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development

26d ago, source: YAHOO!

CARMIEL, Israel, June 8, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX) today announced the appointment of Yael Hayon, Ph.D. as the Company's new Vice ...

Protalix Biotherapeutics, Inc. to Host Earnings Call

19d ago, source: Bloomberg

Before it's here, it's on the Bloomberg Terminal.

Hedge Funds Warming Up To Clearside Biomedical, Inc. (CLSD) Again?

1mon ago, source: Yahoo! Sports

These stocks are Catalyst Biosciences Inc (NASDAQ:CBIO), Gulfport Energy Corporation (NASDAQ:GPOR), Navios Maritime Acquisition Corp (NYSE:NNA), and Protalix BioTherapeutics Inc. (NYSE:PLX).

Protalix BioTherapeutics Inc.

19d ago, source: U.S. News & World Report

Protalix Biotherapeutics, Inc. engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.